Sight-threatening Keratopathy Complicating Anti-TNF Therapy in Crohnʼs Disease

Federica Fascì-Spurio, Alexandra Thompson, S A Madill, Peter Koay, David Mansfield, Jack Satsangi

Inflammatory Bowel Diseases · 2013 · 10 citations · 4 references

Concepts

Abstract

Anti–tumor necrosis factor (TNF) antibodies play an important role in the management of inflammatory bowel disease and rheumatologic and dermatologic conditions. With their widespread use, a number of adverse events have been reported, including “paradoxical” adverse events. This term refers to the intriguing and challenging situation of appearance or aggravation of an inflammatory condition when anti-TNF agents are given to treat a primary inflammatory condition. Paradoxical inflammation may occur with any of the anti-TNF agents commonly used, and it has also been observed that if patients who develop these reactions are switched to another molecule, the paradoxical reaction persists or recurs.1 Generally, paradoxical events do not appear immediately after commencement of therapy, but rather after a certain time of exposure to these medications.2 It is not known why paradoxical reactions occur or what the pathophysiological mechanisms that sustain them are. It is also unclear what predisposes this small subset of patients to develop paradoxical inflammation.3

References

4